Do These Top Marijuana Stock Hold Value In The Cannabis Industry marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
GW Pharmaceuticals plc (NASDAQ:GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.
Epidiolex is the first FDA-authorized CBD medicine for treating children with severe forms of epilepsy. The medicine was first approved for treatments of seizures connected to Lennox-Gastaut syndrome and Dravet syndrome.
Tuberous sclerosis complex is a genetic condition that causes the growth of tumors, usually benign ones, in vital organs, further causing genetic epilepsy.
Around 1 million people in the world suffer from the condition, which causes various types of seizures.